Physician profile
Jerold M Share
NPI 1851350508
$7,172.81
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,340 · 2020: $1,598 · 2021: $1,032 · 2022: $1,245 · 2023: $622 · 2024: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $958.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $2,722.63 | 2019-2023 | Korlym |
| Lilly USA, LLC | $1,188.75 | 2019-2024 | Mounjaro, Jardiance, Lyumjev |
| Astrazeneca Pharmaceuticals Lp | $1,007.46 | 2019 | |
| Amneal Pharmaceuticals LLC | $717.31 | 2019-2024 | Unithroid |
| Sanofi-Aventis U.S. LLC | $367.48 | 2019 | |
| Xeris Pharmaceuticals, INC. | $232.34 | 2022-2024 | Recorlev |
| Novo Nordisk INC | $229.72 | 2019-2024 | Ozempic, Saxenda, Wegovy |
| Mannkind Corporation | $172.88 | 2019-2024 | Afrezza |
| Merck Sharp & Dohme LLC | $154.74 | 2019-2021 | |
| Medtronic, INC. | $64.97 | 2022 | |
| Abbott Laboratories | $53.26 | 2020-2023 | Freestyle Libre 3 |
| Amgen INC. | $52.60 | 2019 | |
| Abbvie INC. | $50.78 | 2019-2020 | |
| Antares Pharma, INC. | $42.13 | 2021-2023 | Nocdurna, Xyosted, Tlando |
| Novartis Pharmaceuticals Corporation | $35.66 | 2022-2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $26.50 | 2019-2020 | |
| Radius Health, INC. | $22.53 | 2019 | |
| Ibsa Pharma INC. | $17.54 | 2020 | |
| Amarin Pharma, INC. | $13.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerold Share listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.